Kodiak Sciences paid its 2 named executives $4.1M in total in FY2025 (Dec). CEO Victor Perlroth, M.D was paid $2.5M of that.
Pay$100 in the stock at the end of FY21 → $33
Pay of each named executive
Victor Perlroth, M.DChief Executive Officer and Chairman of the Board
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) |
4 years
John A. BorgesonExecutive Vice President, Chief Financial Officer and Secretary
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) |
4 years
CEO pay against the pay peers
In FY2025 (Dec), the median CEO pay of the 9 peers with pay on file was $4.8M. The CEO of Kodiak Sciences was paid $2.5M, 48% below the median.
- 1Ocular Therapeutix
- 2MeiraGTx Holdings
- 3AbCellera Biologics
- 4Nektar Therapeutics
- 5Ocugen
- 6Regenxbio
- 7Annexon
- 8Kodiak SciencesThis company
- 9Fate Therapeutics
- 104D Molecular Therapeutics
- 11Allogene TherapeuticsNot disclosed
- 12Coherus BioSciencesNot disclosed
- 13EyePoint PharmaceuticalsNot disclosed
- 14Heron TherapeuticsNot disclosed
- 15Mersana TherapeuticsNot disclosed
- 16Prelude TherapeuticsNot disclosed
- 17RAPT TherapeuticsNot disclosed
- 18Viridian TherapeuticsNot disclosed
'%20fill='%23fff'/%3e%3cpath%20id='fullLogo-2'%20d='M18.156,40.577.011,29.356l0-18.125L18.147,0'%20transform='translate(-0.004%20-0.001)'%20fill='%23fff'/%3e%3cpath%20id='fullLogo-3'%20d='M35.133,14.327H26.354l4.389-7.163L35.127,0l4.395,7.164,4.389,7.163Z'%20transform='translate(-16.985)'%20fill='%2351c0d4'/%3e%3cpath%20id='fullLogo-4'%20d='M51.052,93.782l0-8.211,18.178-3.019Z'%20transform='translate(-32.9%20-53.206)'%20fill='%2300b3cd'/%3e%3cpath%20id='fullLogo-5'%20d='M69.213,11.223l-9.4,3.1L51.035,0Z'%20transform='translate(-32.892%20-0.001)'%20fill='%2300b3cd'/%3e%3cpath%20id='fullLogo-6'%20d='M.01,11.23l9.387,3.1L18.148,0Z'%20transform='translate(-0.006%20-0.001)'%20fill='%2300b3cd'/%3e%3cpath%20id='fullLogo-7'%20d='M75.741,34.672l9.4-3.1,0,18.125Z'%20transform='translate(-48.815%20-20.345)'%20fill='%233fbcd2'/%3e%3cpath%20id='fullLogo-8'%20d='M9.406,34.672l-9.4-3.1,0,18.125Z'%20transform='translate(-0.004%20-20.345)'%20fill='%233fbcd2'/%3e%3cpath%20id='fullLogo-9'%20d='M18.15,93.786l.016-8.209L0,82.56Z'%20transform='translate(0%20-53.21)'%20fill='%233fbcd2'/%3e%3cpath%20id='fullLogo-10'%20d='M59.826,40.3,51.047,58.34l18.178-3.019Z'%20transform='translate(-32.9%20-25.974)'%20fill='%2351c0d4'/%3e%3cpath%20id='fullLogo-11'%20d='M9.393,40.3l8.773,18.041L0,55.321Z'%20transform='translate(0%20-25.971)'%20fill='%2351c0d4'/%3e%3cpath%20id='fullLogo-12'%20d='M35.174,40.3H26.418l4.367,9.019,4.4,9.027,4.373-9.027,4.389-9.02Z'%20transform='translate(-17.026%20-25.974)'%20fill='%238fd4e2'/%3e%3c/svg%3e)
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.